DS
VNDA icon

DRW Securities’s Vanda Pharmaceuticals VNDA Stock Holding History

DRW Securities’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,427
Closed -$224K – 1515
2026
Q1 		$224K Buy
+32,427
New +$250K ﹤0.01% 1049
2016
Q1 		– Sell
-32,500
Closed -$303K – 93
2015
Q4 		$303K Buy
+32,500
New +$324K 0.03% 65

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DRW Securities's VNDA Position: Q2 2026 in Review

DRW Securities sold out of Vanda Pharmaceuticals (VNDA) in Q2 2026, closing a stake of 32,427 shares — an estimated $224K sold.

DRW Securities first reported a position in VNDA in Q4 2015 and held it in 2 quarters. The position peaked at $303K in Q4 2015. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • DRW Securities reported no remaining Vanda Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • DRW Securities sold 32,427 Vanda Pharmaceuticals shares in Q2 2026, an estimated $224K.
  • DRW Securities first reported a position in Vanda Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • DRW Securities's Vanda Pharmaceuticals position peaked at $303K in Q4 2015.
  • 173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.